Clinical Prescribing System Resources for transitioning patients from Levemir® (insulin detemir)
This site and associated resources have been funded by Novo Nordisk UK and developed in conjunction with Oberoi Consulting. They are intended for Healthcare Professionals (HCPs) and Other Relevant Decision Makers (ORDMs) who have population level decision making capability for their Healthcare Organisation. Clinical discretion should be exercised by the HCP to determine the best management plan for their patients.
Adverse Event Reporting
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse Events should also be reported to Novo Nordisk UK (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.